In this issue of Leukemia and Lymphoma, Chari and colleagues expand the armamentarium for the treatment of multiple myeloma to include the Bruton tyro-sine kinase inhibitor (BTK) ibrutinib. In this phase-1 trial, ibrutinib at a dose of 840 mg (twice the dose used for chronic lymphatic ...
multiple myeloma cureplasma cell diseaseA 52-year-old man with a plasmacytoma of the body of T-10 in February 1965 returned 6 months later with multiple myeloma characterized by bone pain, osteolytic lesions, and IgD 位 monoclonal protein in the serum, 6.1 g of Bence Jones protein in the ...
Smoldering (asymptomatic) multiple myeloma (SMM) was first described in 1980 by Kyle and Greipp. SMM is a diagnosis largely based on laboratory findings and represents an intermediate clinical stage between monoclonal gammopathies (MGUS) and multiple myeloma (MM) [1]. At the end of 2014, Inte...
About Us Moving Mountains 4 Multiple Myeloma is an award-winning collaboration between the Multiple Myeloma Research Foundation (MMRF) and CURE to raise research funds, awareness and hope for myeloma patients. Patients, caregivers, myeloma doctors and nurses and myeloma loved ones take on challenging ...
Despite significant advances in the treatment of multiple myeloma which had led to unprecedented rates of response and survival, patients still relapse, and cure remains elusive. We propose in this review a roadmap to achieve the dream of cure for multiple myeloma based on five complementary strate...
“The future is bright, and the cure is near.” References Bahlis NJ, Quach H, Baz R, et al. Venetoclax in combination with daratumumab and dexamethasone elicits deep, durable responses in patients with t(11;14) relapsed/refractory multiple myeloma: update...
“We're thinking about potentially curative strategies for multiple myeloma knowing that we have so many effective treatments,” he told Healio | HemOnc Today. “I think the field is heading in the direction of a functional cure and we will probably get there within th...
“We’re ready to bridge the gap from long-term remission to cure, by identifying the best treatments at the best time to achieve the best objective, our objective being a new definition of cure based on a complete eradication of any residual myeloma,” Durie said. In an interview with...
A. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy. Ann Oncol 11 Suppl 1, 55–8 (2000). 7. Sakaguchi, S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22, 531–...
This is a quite extraordinary story told in an exceptionally authoritative way. At the age of 54, Michael Gearin-Tosh was diagnosed in 1995 with myeloma, bone marrow cancer, one of the most lethal cancers known. The usual survival time with treatment is two to three years; without it, one...